Aims To study the effect of eprosartan, a nonbiphenyl tetrazole angiotensin II receptor antagonist, on digoxin pharmacokinetics in a randomized, open-label, two period, period balanced crossover study in 12 healthy men. Methods Each subject received a single 0.6 mg oral dose of digoxin (LanoxicapsA 0.2 mg/capsule, Glaxo Wellcome) alone or following 4 days of dosing with eprosartan 200 mg orally every 12 h. Each study period was separated by a 14 day washout interval. Serial blood samples were obtained for up to 96 h after each digoxin dose for determination of digoxin pharmacokinetics. The effect of eprosartan on digoxin pharmacokinetics was assessed through an equivalence-type approach using AUC(0, t∞) as the primary endpoint. Results For AUC(0, t∞), the ratio of digoxin+eprosartan5digoxin alone was 0.99 with a 90% confidence interval (CI) of [0.90, 1.09]. For C max , the ratio was 1.00 with a 90% CI of [0.86, 1.17]. t max was similar for both regimens. Both regimens were safe and well tolerated. Conclusions Based on AUC and C max data, it can be concluded that eprosartan has no effect on the pharmacokinetics of a single oral dose of digoxin.
Introduction phosphamide, vincristine and bleomycin) [5] . Certain antibiotics including sulphasalazine, neomycin and aminosalicylic The renin-angiotensin system plays a vital role in the normal homeostatic regulation of cardiovascular and renal function.
acid reduce digoxin absorption while others, including erythromycin and tetracycline, increase the bioavailability of It is often activated in diseases such as hypertension, congestive heart failure and chronic renal failure and plays a digoxin [5] . Antiarrhythmic drugs, such as quinidine and amiodarone, and certain calcium channel blockers, particucentral role in the pathophysiology of these disorders. A number of non-peptide angiotensin II antagonists have larly verapamil, can markedly increase steady-state serum digoxin levels [6] . recently been described [1, 2] that differ from the angiotensin converting enzyme inhibitors in that they inhibit angiotensin
The usual therapeutic plasma concentration range for digoxin is 0.9-2 ng ml −1 , with the maximum tolerable II action directly at the receptor level rather than blocking angiotensin II synthesis. Eprosartan is a new nonbiphenyl concentration usually around 2 ng ml −1 [7] . However, the optimal therapeutic concentration of digoxin shows great tetrazole angiotensin II receptor antagonist currently in clinical development for essential hypertension. In the rat inter-individual variation, as does the toxic concentration. Any change in this concentration, as a consequence of a and dog, eprosartan has been shown to be a potent and highly selective competitive antagonist of angiotensin II at pharmacokinetic interaction with other drugs used concurrently, may therefore lead either to a clinically significant the AT1 receptor [2] [3] [4] .
Identifying and characterizing drug interactions with reduction in the pharmacologic response or to an increase in the incidence of unwanted toxic effects. Since a digoxin are important because digoxin is widely used in cardiovascular disorders and has a narrow therapeutic index.
considerable number of patients requiring therapy with eprosartan are expected to be on concurrent digitalis therapy, Numerous pharmacological agents have been shown to produce clinically significant interactions with digoxin.
it is desirable to investigate any potential effect of eprosartan on plasma digoxin concentrations. Drugs which reduce digoxin absorption include antacids (aluminium hydroxide, magnesium hydroxide and
The objectives of this study were to evaluate the effect of steady state oral dosing of eprosartan on the magnesium trisilicate), antidiarrheals (kaolin and pectin), pharmacokinetics of a single oral dose of digoxin. The study design is similar to that proposed by Antman and Lack of an interaction of eprosartan on the pharmacokinetics of digoxin was assessed through an equivalence-type the start of the study, and the study was conducted in accordance with the Declaration of Helsinki. Subjects gave approach which used a two one-sided tests procedure [9] . Eprosartan would be considered to have no effect on the written informed consent prior to enrolling in the study.
This was a randomized, open-label, two period, period pharmacokinetics of digoxin if the 90% confidence interval (CI) for the ratio of the AUC values was completely balanced crossover study. Subjects were randomly assigned to receive digoxin alone or digoxin plus eprosartan during contained within the range [0.70, 1.43]. The parameters AUC(0, t∞), AUC and C max were ln-transformed prior to period 1. Then, after a dose-free interval of at least 14 days following completion of period 1, subjects received the separate analysis of variance (ANOVA) with the effects of sequence, subject, period and regimen included in the model alternate regimen in period 2. For the digoxin alone regimen, digoxin (LanoxicapsA 0.2 mg/capsule, Glaxo
[10]. t max was analysed using a non-parametric method which took into account possible period effects [11]. Wellcome) was given as a single oral dose of 0.6 mg. For the digoxin plus eprosartan regimen, eprosartan 200 mg was given twice daily for 7 days, with digoxin 0.6 mg given as Results a single oral dose on the morning of day 4.
Twelve healthy, non-smoking, male subjects between 18
The mean age of the 12 subjects was 31 years (range 24-39 years) and mean weight was 78.8 kg (range 60-102 kg ). A and 45 years of age, inclusive, were selected for study participation. All subjects had a medical history, complete total of six adverse experiences (AE) were reported for four subjects following treatment with study medication. Of physical examination, 12-lead electrocardiogram (ECG), haematology, sitting blood pressure and pulse rate, and these, two AEs (hypertonia and hyperbilirubinemia) occurred following administration of digoxin alone and four AEs clinical laboratory tests within 15 days prior to the start of the study. In addition, subjects underwent screening for (headache, fatigue, eye pain and abdominal pain) occurred following digoxin plus eprosartan. All AEs were considered drugs of abuse and were tested for hepatitis B and C and HIV; negative results were required for inclusion in the mild to moderate in nature. Except for the occurrence of hypertonia which was assessed as not related to digoxin study. Subjects had a negative urine drug screen and were without any clinically relevant abnormalities on screening administration, all AEs were considered to be possibly related to study medication. history, physical or laboratory examinations.
For each study session, blood samples for pharmacokinetic Pharmacokinetic data were available for all 12 subjects following oral administration of digoxin alone and digoxin analysis of digoxin were drawn into heparinized tubes prior to digoxin dosing, and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, co-administered with eprosartan. However, t D could not be accurately determined for three subjects on one of their two 24, 36, 48, 60, 72, 84 and 96 h following digoxin dosing. A follow-up medical examination and clinical laboratory dosing occasions because a non-quantifiable concentration was reported in the terminal phase followed by a quantifiable tests were performed within 7 to 10 days following the last pharmacokinetic sampling period.
concentration. Following a single oral dose of digoxin either alone or with steady state eprosartan, maximum plasma Plasma concentrations of digoxin were determined by radioimmunoassay using a I 125 -labeled digoxin derivative.
concentrations of digoxin occurred at approximately 1.5 h following dosing. Thereafter plasma concentrations of The concentration range of the assay was 0.10 to 3.63 ng ml −1 based on a 50 ml plasma sample. The lower digoxin declined in an apparent biexponential manner. Mean (s.d.) pharmacokinetic parameters of digoxin following limit of quantification was 0.10 ng ml −1 . A three-run validation was performed to verify the precision and accuracy oral administration of digoxin alone or with eprosartan at steady-state are presented in Table 1 . The mean digoxin of the assay. The within-run precision for the assay at nominal concentrations of 0.10, 0.25, 1.01, and plasma concentration-time profiles for each regimen are presented in Figure 1 . 3.63 ng ml −1 was 8.4, 3.7, 1.7, and 2.6%, respectively. The between-run precision of the assay at these concentrations In the majority of subjects, t D ,z could be determined on each study day and was approximately 40 h for digoxin was 3.2, 3.2, 2.1, and 2.1%, respectively. The mean accuracy of the assay at concentrations of 0.10, 0.25, 1.01, and alone and 47 h for digoxin plus eprosartan. However, the time period over which t D ,z was calculated was less than 3.63 ng ml −1 was 103, 99, 101, and 101%, respectively.
Pharmacokinetic analysis of the individual digoxin plasma three half-lives. AUC values generally had extrapolated areas of greater than 20% but less than 40%. Therefore, both t D ,z concentration-time data was conducted using noncompartmental analysis. The following pharmacokinetic and AUC estimates should be viewed with caution. Since AUC values based on a large extrapolated area may be parameters were derived: maximum observed digoxin plasma concentration (C max ), time at which C max occurred (t max ), inaccurate [12] , AUC(0, t∞) was used as the primary endpoint for statistical analysis and AUC was used as a secondary terminal phase rate constant (l z ) and the corresponding halflife (t D ,z ). l z was determined using unweighted linear endpoint.
The results of the statistical analysis are also presented in regression analysis of at least three log-transformed concentrations visually assessed to be on the linear portion of the Table 1 . The 90% CI for the ratios of the geometric means eprosartan had no effect on the pharmacokinetics of single-dose digoxin.
In a recent review and appraisal of the study methodology associated with digoxin interaction studies, Antman and colleagues discussed the merits and limitations of four study designs [8] . These designs encompassed single and multiple doses of digoxin in cardiac patients and normal volunteers. The authors noted that a single dose digoxin pharmacokinetic study in healthy volunteers serves as a valuable screen for potential digoxin drug interactions. If a potential drug interaction is observed with this screening study or if a clinically relevant pharmacokinetic interaction is expected (e.g., based on other drugs within the class or previous experience with the compound in question), further testing with multiple doses in healthy volunteers or single and multiple dose studies in cardiac patients may then be warranted. Conversely, if no drug interaction is noted with this screening study and if no clinically relevant pharmacokinetic drug interactions are anticipated, then no further pharmacokinetic studies may be needed beyond the initial screen.
Eprosartan is primarily eliminated via the faeces as colleagues, the likelihood of an interaction between eprosartan and digoxin was considered to be remote, and so the for digoxin+eprosartan5digoxin alone for AUC(0, t∞), AUC single dose digoxin design in healthy volunteers was selected and C max were completely contained within the equivalence as the most appropriate initial study design. range [0.70, 1.43]. Hence, eprosartan can be considered to Eprosartan was safe and well tolerated when cohave had no effect on the pharmacokinetics of digoxin.
administered with a single oral dose of digoxin. The adverse experiences that occurred were mild to moderate in nature and did not require any corrective therapy. The results of Discussion the pharmacokinetic analysis indicate that a clinically relevant Eprosartan is being developed for the treatment of mild to interaction between eprosartan and digoxin is unlikely at severe essential hypertension. It is likely that eprosartan will the doses evaluated in this study. be prescribed concomitantly with digoxin, and thus the potential effect of eprosartan on digoxin pharmacokinetics References was the focus of this study.
The present study was designed with these considerations 
